NIBEC Co., Ltd. (KOSDAQ:138610)
South Korea · Delayed Price · Currency is KRW 25,600
-500 (-1.92%)
At close: Apr 9, 2026
NIBEC Revenue
In the year 2025, NIBEC had annual revenue of 32.72B KRW with 33.27% growth. NIBEC had revenue of 6.14B in the quarter ending December 31, 2025, a decrease of -3.78%.
Revenue
32.72B
Revenue Growth
+33.27%
P/S Ratio
8.95
Revenue / Employee
340.82M
Employees
96
Market Cap
292.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.72B | 8.17B | 33.27% |
| Dec 31, 2024 | 24.55B | 8.85B | 56.33% |
| Dec 31, 2023 | 15.70B | -5.97B | -27.53% |
| Dec 31, 2022 | 21.67B | 8.05B | 59.04% |
| Dec 31, 2021 | 13.63B | 7.27B | 114.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 100.17B |
| ISU Abxis | 56.67B |
| Genome & Company | 24.59B |
| S.Biomedics | 16.55B |
| Bio Solution | 15.20B |
| TiumBio | 12.29B |
| Kangstem Biotech | 3.57B |
| Y-Biologics | 2.91B |